Mirataz News

Completion of the Acquisition of Mirataz

/in /by

Dechra Acquires Worldwide Rights to the Mirataz® Product Portfolio Further to the announcement on 17 March 2020, Dechra is pleased to announce that the acquisition of the worldwide rights of the Mirataz® product portfolio from Kindred Biosciences Incorporated has completed. The addition of Mirataz significantly enhances the Dechra portfolio and is fully complementary to its […]

Read more

Dechra Acquires Worldwide Rights to the Mirataz® Product Portfolio

/in /by

The Board of Dechra is pleased to announce that it has agreed terms to acquire the worldwide rights to the Mirataz® product portfolio from Kindred Biosciences Incorporated for a total consideration of USD43.0 million (£35.0 million)1, and a royalty on future sales. The acquisition will be financed from the Group’s existing cash and borrowing facilities. […]

Read more

Mirataz is indicated for the management of weight loss in cats.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information, click here.

US Patent 10,603,272
Mirataz® is a registered trademark of Dechra Ltd.